Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 2OTHER_GOV 1OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Neurotoxicity Syndromes 1Drug-Related Side Effects and Adverse Reactions 1Breast Neoplasms 1

Interventions

human papillomavirus vaccine, L1 type 16, 18 3Radiotherapy 3Propranolol 3Cisplatin 3entecavir 2Tranexamic Acid 2Pemetrexed 2Metformin 2Erythromycin 2Epinephrine 2Cyclophosphamide 2Chemoradiotherapy 2Bortezomib 2ulipristal acetate 1tislelizumab 1plerixafor 1lobaplatin 1ledipasvir 1eribulin 1endostar protein 1dolutegravir 1colistinmethanesulfonic acid 1cetrorelix 1acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1XELOX 1Vancomycin 1Vacuum Curettage 1Vaccination 1Suction 1Sofosbuvir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × OTHER_GOV × eribulin × Clear all
NCT02864030 2021-03-04

PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment

Oncologia Medica dell'Ospedale Fatebenefratelli

Phase 4 Completed
200 enrolled
Breast

Breast Neoplasms, Neurotoxicity Syndromes, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡